Paper Details

  1. Home
  2. Paper Details

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

Author: BannooSelina, DobbsStephen, EssapenSharadah, HerodJonathan, HookJane, JaysonGordon C, KehoeSean, KitchenerHenry, LopesTito, LuesleyDavid, MascarenhasMonica, McCluggageGlenn, NankivellMatthew, ParmarMahesh, PerrenTimothy, SwartAnn-Marie, TwiggJeremy

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The standard treatment for women with suspected advanced ovarian cancer involves surgery followed by platinum-based chemotherapy. This study examines the effectiveness and safety of using platinum-based chemotherapy as the primary treatment, followed by delayed surgery.
Paper Details　
Original Abstract of the Article :
The international standard of care for women with suspected advanced ovarian cancer is surgical debulking followed by platinum-based chemotherapy. We aimed to establish whether use of platinum-based primary chemotherapy followed by delayed surgery was an effective and safe alternative treatment regi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0140-6736(14)62223-6

データ提供：米国国立医学図書館（NLM）

Primary Chemotherapy vs. Primary Surgery for Ovarian Cancer: A New Approach

The fight against ovarian cancer is a complex battle, requiring a multi-faceted approach. This study delves into the world of ovarian cancer treatment, examining two distinct strategies: primary chemotherapy followed by delayed surgery and the traditional approach of primary surgery followed by chemotherapy. The researchers conducted a large-scale, randomized controlled trial to compare the effectiveness and safety of these two treatment approaches.

Primary Chemotherapy: A Viable Alternative

The study found that primary chemotherapy followed by delayed surgery was an effective and safe alternative treatment regimen for women with newly diagnosed advanced ovarian cancer. This finding challenges the traditional approach and suggests that primary chemotherapy can be a valuable option for patients with advanced disease. This approach may offer potential benefits, such as improved patient survival and quality of life.

Navigating the Treatment Landscape

The treatment of ovarian cancer is a complex and ever-evolving landscape. This study offers a new perspective on the potential benefits of primary chemotherapy as a viable treatment option. The research underscores the importance of carefully evaluating individual patient factors and tailoring treatment approaches to their specific needs.

Dr.Camel's Conclusion

This research represents a significant advance in the field of ovarian cancer treatment. The study highlights the effectiveness and safety of primary chemotherapy as a viable alternative to the traditional approach, offering hope for better outcomes for patients with advanced disease.
Date :
  1. Date Completed 2015-08-03
  2. Date Revised 2023-03-01
Further Info :

Pubmed ID

26002111

DOI: Digital Object Identifier

10.1016/S0140-6736(14)62223-6

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.